(NASDAQ:SIFY), Revenues of INR 11596 Million. EBITDA of INR 2470 Million. Loss for the period INR 329 Million. CHENNAI, India, Jan. 12, 2026 (GLOBE NEWSWIRE) — DETAILS OF EARNING CALL January 13, 2026 | 8:30 AM ET | 07:00 PM IST Participant Dial in: To join: +1-888-506-0062 (Toll Free in the U.S. or Canada) or […]
(Other OTC:INNMF),(OTC US:INNMF),(AUST:ATX.AX), HIGHLIGHTS Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal Cancer Symposium Updated data analysis continues to show that Narmafotinib combination compares favourably with gemcitabine and Abraxane combination alone Melbourne, Australia, Jan. 12, 2026 (GLOBE NEWSWIRE) — Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF),
(NasdaqGM:ACTU), Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy alone Elraglusib combination reduced the risk of death by 38% compared with gemcitabine/nab-paclitaxel alone, with increased durable survival observed beyond 24 months CHICAGO and FORT WORTH, Texas, Jan. 12, 2026 (GLOBE NEWSWIRE) — Actuate Therapeutics,
(NasdaqGM:VWAV),(NYSE:IONQ),(NASDAQ:KTOS),(NASDAQ:RGTI),(NYSE MKT:UAVS), NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) — Market News Updates News Commentary – Quantum computing is moving from the lab into real-world military use, and defense organizations are paying close attention. Unlike traditional computing, quantum systems can process extraordinarily complex variables at once, which is highly relevant for modern military operations. Applications
Sify reports Consolidated Financial Results for Q3 FY 2025-26 GlobeNewswire January 12, 2026 Revenues of INR 11596 Million. EBITDA of INR 2470 Million. Loss for the period INR 329 Million. CHENNAI, India, Jan. 12, 2026 (GLOBE NEWSWIRE) — DETAILS OF EARNING CALL January 13, 2026 | 8:30 AM ET | 07:00 PM IST Participant Dial
ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM GlobeNewswire January 12, 2026 HIGHLIGHTS Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal Cancer Symposium Updated data analysis continues to show that Narmafotinib combination compares favourably with gemcitabine and Abraxane combination alone Melbourne, Australia, Jan.
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026 GlobeNewswire January 12, 2026 Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus gemcitabine/nab-paclitaxel
Defense Spending Is Accelerating the Commercialization of Quantum Computing Defense Adoption Accelerates as Global Quantum Computing Revenues Are Poised to Reach $2 Billion in 2026 GlobeNewswire January 12, 2026 NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) — Market News Updates News Commentary – Quantum computing is moving from the lab into real-world military use, and
MINNEAPOLIS, Jan. 12, 2026 (GLOBE NEWSWIRE) — Vortex Doors, a nationwide leader in commercial and industrial door solutions, is proud to announce the grand opening of its new Minneapolis service center. This expansion brings fast, reliable, and professional door repair, maintenance, and replacement services to businesses throughout Minneapolis, St. Paul, and the greater Twin Cities
Vortex Doors Expands into Minneapolis, Minnesota – Now Offering Expert Door Repair and Maintenance Services GlobeNewswire January 12, 2026 MINNEAPOLIS, Jan. 12, 2026 (GLOBE NEWSWIRE) — Vortex Doors, a nationwide leader in commercial and industrial door solutions, is proud to announce the grand opening of its new Minneapolis service center. This expansion brings fast, reliable,